Author

Muloongo Simuzingili

Observed names: M Simuzingili, Simuzingili, Muloongo

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Centers for Disease Control and Prevention, National Center for Injury Prevention and Control

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Centers for Disease Control and Prevention, National Center for Injury Prevention and Control

ORCID: 0009-0003-3738-6189

Observed ORCID: 0009-0003-3738-6189

OpenAlex ID: A5115631465

Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021–February 2022

2024 · Yangyang Deng, Yun Kim, et al. · Open Forum Infectious Diseases · 5

Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland

2026 · Muloongo Simuzingili, Andrea Favre-Bulle, et al. · Journal of Medical Economics · 4

PDF

The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥18 in Germany

2026 · Muloongo Simuzingili, Zinan Yi, et al. · Expert Review of Vaccines · 2

Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain

2026 · Muloongo Simuzingili, Silvia Fernández-Soberón, et al. · Vaccine · 1

The health and economic burden of invasive pneumococcal diseases attributable to PCV21 or PCV20 serotypes among adults aged ≥18 years in Switzerland

2026 · Muloongo Simuzingili, Andrea Favre-Bulle, et al. · Vaccine X · 1

Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany

2026 · Muloongo Simuzingili, Peter P. Mueller, et al. · Figshare

The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

2026 · Peter P. Mueller, Muloongo Simuzingili, et al. · medRxiv

Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany

2026 · Muloongo Simuzingili, Peter P. Mueller, et al. · Expert Review of Vaccines

PDF

Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21

2026 · Muloongo Simuzingili, Zinan Yi, et al. · Figshare

Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21

2026 · Muloongo Simuzingili, Zinan Yi, et al. · Journal of Medical Economics

The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥ 45 years in Spain

2026 · Muloongo Simuzingili, Silvia Fernández-Soberón, et al. · BMC Public Health

Cross-Sectional Analysis of Contextual Factors Associated With Sexual Violence Against Children and Youth in Low- and Middle-Income Countries

2026 · Stephanie Spaid Miedema, Muloongo Simuzingili, et al. · Journal of Interpersonal Violence

The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥18 in Germany

2026 · Simuzingili, Muloongo, Yi, Zinan, et al. · Figshare

Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland

2026 · Simuzingili, Muloongo, Favre-Bulle, Andrea, et al. · Figshare

Evaluating the Potential Lifetime Health and Economic Impact of V116, an Adult-Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Adults Aged ≥45 Years in Spain

2025 · Muloongo Simuzingili, Silvia Fernández-Soberón, et al. · SSRN Electronic Journal

EE126 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Switzerland

2024 · M Simuzingili, N Cossrow, et al. · Value in Health

PDF

EE636 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Spain

2024 · M Simuzingili, S Fernandez, et al. · Value in Health

PDF

EE798 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Germany

2024 · M Simuzingili, Z Yi, et al. · Value in Health

Works count: 18

Citation count: 13

H-index: 2

I10-index: